At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 76 target
Drug / intervention
BL-B01D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIa/IIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 for Urinary System Tumor and Solid Tumor. Currently recruiting, targeting 76 participants across 1 site.
Detailed Summary
Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary System Tumor, Solid Tumor
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2Recruiting
20242025202620272028
First PostedMar 2023
Enrollment StartApr 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedMar 27, 2023
Enrollment StartApr 20, 2023
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 3.3 years agoPrimary completion in 5 months
Interventions
BL-B01D1drug
Administration by intravenous infusion